0.235

1.26% -0.003

Cellectar Biosciences Inc (CLRB)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.238

Offen:

$0.24

24-Stunden-Volumen:

2.16M

Relative Volume:

1.50

Marktkapitalisierung:

$9.70M

Einnahmen:

Nettoeinkommen (Verlust:

$-37.75M

KGV:

-0.0708

EPS:

-3.32

Netto-Cashflow:

$-30.91M

1W Leistung:

-9.62%

1M Leistung:

-84.94%

6M Leistung:

-91.61%

1J Leistung:

-90.86%

1-Tages-Spanne:

$0.23

$0.2495

1-Wochen-Bereich:

$0.224

$0.2785

52-Wochen-Spanne:

$0.224

$4.45

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Firmenname

Cellectar Biosciences Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(608) 441-8120

Adresse

100 CAMPUS DRIVE, FLORHAM PARK, NJ

Mitarbeiter

Twitter

@CellectarBio

Nächster Verdiensttermin

2024-12-18

Neueste SEC-Einreichungen

CLRB's Discussions on Twitter

Vergleichen Sie CLRB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CLRB Cellectar Biosciences Inc	0.235	9.70M	0	-37.75M	-30.91M	-3.25
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-05	Fortgesetzt	Ladenburg Thalmann	Buy
2020-07-01	Eingeleitet	Oppenheimer	Outperform
2020-01-21	Fortgesetzt	ROTH Capital	Buy
2019-09-13	Eingeleitet	ROTH Capital	Buy
2016-12-21	Eingeleitet	Ladenburg Thalmann	Buy

Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten

Dec 20, 2024

Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World

Dec 20, 2024

Dec 19, 2024

Oppenheimer Downgrades Cellectar Biosciences (CLRB) - MSN

Dec 19, 2024

Dec 16, 2024

Roth Capital Has Optimistic Outlook of CLRB Q1 Earnings - Defense World

Dec 16, 2024

Dec 13, 2024

Cellectar Biosciences Implements Workforce Reduction Plan to Enhance Operational Efficiency - Defense World

Dec 13, 2024

Dec 12, 2024

Cellectar Biosciences (FRA:NV4) 10-Year Sharpe Ratio : -0.19 (As of Dec. 12, 2024) - GuruFocus.com

Dec 12, 2024

Cellectar Biosciences (FRA:NV4) 3-Year Sortino Ratio : -0.47 (As of Dec. 12, 2024) - GuruFocus.com

Dec 12, 2024

Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline - Investing.com

Dec 12, 2024

Dec 11, 2024

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut - MarketWatch

Dec 11, 2024

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga

Dec 11, 2024

Cellectar Biosciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Dec 11, 2024

Dec 10, 2024

Cellectar stock plunges 50% post-market on restructuring news - MSN

Dec 10, 2024

Cellectar stock plunges 50% post-market on restructuring news (NASDAQ:CLRB) - Seeking Alpha

Dec 10, 2024

CLRBCellectar Biosciences INC NEW Latest Stock News & Market Updates - StockTitan

Dec 10, 2024

Cellectar refocuses on solid tumor radiotherapies - Investing.com

Dec 10, 2024

Cellectar Biosciences Provides Strategic Update on Clinical - GlobeNewswire

Dec 10, 2024

Cellectar Shifts Strategy After FDA Feedback, Cuts 60% Workforce to Advance Cancer Pipeline - StockTitan

Dec 10, 2024

Dec 06, 2024

Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp - Barchart

Dec 06, 2024

Waldenstrom Macroglobulinemia Market Growth to Accelerate - openPR

Dec 06, 2024

Cellectar Biosci stock hits 52-week low at $1.38 By Investing.com - Investing.com Canada

Dec 06, 2024

Dec 05, 2024

Cellectar Biosci stock hits 52-week low at $1.38 - Investing.com

Dec 05, 2024

Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target - Quantisnow

Dec 05, 2024

Dec 02, 2024

This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? - AOL

Dec 02, 2024

Dec 01, 2024

Cellectar Biosciences (STU:NV4) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Nov 29, 2024

Cellectar Biosciences (STU:NV4) Volatility : 73.35% (As of Nov. 29, 2024) - GuruFocus.com

Nov 29, 2024

Cellectar Biosciences (STU:NV4) Total Stockholders Equity : €13.66 Mil (As of Sep. 2024) - GuruFocus.com

Nov 29, 2024

Nov 28, 2024

Cellectar Biosciences (STU:NV4) PE Ratio : At Loss (As of Nov. 28, 2024) - GuruFocus.com

Nov 28, 2024

Cellectar Biosciences (STU:NV4) Other Long Term Assets : €0.03 Mil (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Cellectar Biosciences (STU:NV4) Current Accrued Expense : €7.48 Mil (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Cellectar Biosciences (STU:NV4) Quick Ratio : 1.77 (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Nov 27, 2024

Cellectar Biosciences (FRA:NV4) 3-Year Book Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 27, 2024

Cellectar Biosciences (FRA:NV4) Margin of Safety % (DCF FCF Based) : N/A (As of Nov. 26, 2024) - GuruFocus.com

Nov 27, 2024

Nov 25, 2024

CLRB (Cellectar Biosciences) EPS without NRI : $-2.17 (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 24, 2024

12,500 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Purchased by Oppenheimer & Co. Inc. - Defense World

Nov 24, 2024

Nov 23, 2024

Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com

Nov 23, 2024

Nov 22, 2024

Roth Capital Analysts Decrease Earnings Estimates for CLRB - Defense World

Nov 22, 2024

Nov 21, 2024

Oppenheimer Lowers Cellectar Biosciences (NASDAQ:CLRB) Price Target to $12.00 - Defense World

Nov 21, 2024

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 21, 2024

Cellectar Signs Critical Radioisotope Supply Deal for Cancer Drug Development | CLRB Stock News - StockTitan

Nov 21, 2024

Roth Capital Has Bearish Forecast for CLRB FY2024 Earnings - MarketBeat

Nov 21, 2024

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides Corporate Update - Defense World

Nov 21, 2024

Equities Analysts Offer Predictions for CLRB Q1 Earnings - Defense World

Nov 21, 2024

Nov 20, 2024

What is Roth Capital's Estimate for CLRB Q1 Earnings? - MarketBeat

Nov 20, 2024

Nov 19, 2024

Oppenheimer cuts Cellectar Biosciences stock target, outperform on Q3 financials - Investing.com UK

Nov 19, 2024

Oppenheimer Has Lowered Expectations for Cellectar Biosciences (NASDAQ:CLRB) Stock Price - MarketBeat

Nov 19, 2024

Earnings call: Cellectar Biosciences delays NDA submission for iopofosine I 131 - Investing.com

Nov 19, 2024

Nov 18, 2024

Cellectar Biosciences Reports Q3 2024 Financial Results - TipRanks

Nov 18, 2024